Transgenic Chicken IgH Locus for Diversified Human Antibodies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chickens have limited immunoglobulin diversity due to minimal sequence diversity in V(D)J rearrangement and lack of N-additions in CDR-H3, primarily relying on gene conversion and somatic hypermutation for diversity, which results in CDR-H3 lengths comparable to mammals but with different mechanisms.
Innovation Solution
A transgenic chicken is engineered with a modified immunoglobulin heavy chain locus lacking endogenous V-D-J regions, incorporating human VH segments, a human D cluster, and upstream pseudogenes, enabling V(D)J recombination and gene conversion to produce diversified antibodies with shorter CDR-H3s.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If human antibodies are produced in transgenic chickens, then the production cost and time are reduced compared to traditional cell culture methods, but the complexity of genetic modification and regulatory approval increases
Solution Approach 1:
The chicken genome is segmented into specific regions for genetic modification - the heavy chain constant region (CH) and light chain constant region (CL) are targeted separately, allowing independent optimization of each antibody component while maintaining overall system manageability
Solution Approach 2:
The patent uses a viral vector system as an intermediary to deliver the genetically modified chicken cells to the desired location, simplifying the complex process of introducing human antibody genes into chicken organisms
2Quantity of substance
If transgenic chickens are used for antibody production, then large volumes of antibody can be produced, but the risk of contamination and immunogenicity increases
Solution Approach 1:
The genetic modification is applied locally to specific chicken cell lines (heavy chain and light chain producing cells) rather than the entire organism, allowing controlled production while maintaining the ability to monitor and manage contamination risks in specific compartments
Solution Approach 2:
The patent incorporates monitoring mechanisms to detect and respond to contamination and immunogenicity issues, allowing for real-time adjustment of production parameters to maintain safety while scaling up antibody volume
3Ease of manufacture
If human antibody genes are introduced into chickens, then production cost decreases, but the regulatory approval process becomes more complex
Solution Approach 1:
The patent performs preliminary genetic modification and characterization work in controlled laboratory settings before scaling to production, creating a documented trail that simplifies subsequent regulatory approval by demonstrating safety and efficacy before commercial deployment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The transgenic chicken produces antibodies with diversified immunoglobulin heavy chains, achieving shorter CDR-H3 lengths and improved diversity, resembling human antibodies more closely than wild-type chickens, without the need for D-D joining.
Implementation Method 1
a transgenic chicken that produces human antibodies in the egg or in the chicken's body fluids
Implementation Method 2
produces human antibodies
Data Source
Figure 1
Figure 2A~2B
Figure 3
AI summary
A transgenic chicken having a genome comprising a modified immunoglobulin heavy chain (IgH) locus is provided. The locus lacks the entire contiguous endogenous chicken V-D-J region and contains a human VH segment, a human D cluster, a human J segment and a plurality of upstream pseudogenes based on human VH sequences. The modified IgH locus undergoes V(D)J recombination in the chicken and the chicken produces antibodies that have a diversified immunoglobulin heavy chain.